Integra LifeSciences Holdings Corporation (IART) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Devices
EV/EBITDA
↓
13.17
↓-28% vs avg
5yr avg: 18.35
30Y Low10.1·High40.8
P/FCF
↑
N/A
—
5yr avg: 40.26
30Y Low9.3·High70.0
P/B Ratio
↓
1.03
↓-50% vs avg
5yr avg: 2.05
30Y Low0.9·High4.8
ROE
↓
-39.9%
↑-1193% vs avg
5yr avg: -3.1%
30Y Low-41%·High20%
Debt/EBITDA
↑
9.27
↑+22% vs avg
5yr avg: 7.58
30Y Low0.2·High13.8
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IART Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Integra LifeSciences Holdings Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $953M | $1.7B | $3.5B | $4.7B | $5.7B | $5.5B | $5.0B | $3.8B | $3.8B | $3.4B |
| Enterprise Value | $2.9B | $2.8B | $3.5B | $4.9B | $5.9B | $6.9B | $6.7B | $6.3B | $5.0B | $5.5B | $4.0B |
| P/E Ratio → | -2.08 | — | — | 51.85 | 25.96 | 33.83 | 41.35 | 100.48 | 62.64 | 58.37 | 45.63 |
| P/S Ratio | 0.67 | 0.58 | 1.08 | 2.27 | 3.01 | 3.71 | 4.03 | 3.32 | 2.59 | 3.19 | 3.42 |
| P/B Ratio | 1.03 | 0.91 | 1.13 | 2.20 | 2.60 | 3.40 | 3.65 | 3.56 | 2.77 | 3.94 | 4.05 |
| P/FCF | — | — | 69.96 | 47.87 | 21.54 | 21.66 | 39.54 | 52.02 | 31.23 | 53.30 | 49.18 |
| P/OCF | 21.66 | 18.92 | 13.50 | 25.00 | 17.71 | 18.33 | 27.14 | 21.78 | 19.07 | 33.06 | 29.18 |
P/E links to full P/E history page with 30-year chart
IART EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Integra LifeSciences Holdings Corporation's enterprise value stands at 13.2x EBITDA, 28% below its 5-year average of 18.3x. The Healthcare sector median is 14.1x, placing the stock at a 7% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.68 | 2.16 | 3.18 | 3.76 | 4.46 | 4.90 | 4.15 | 3.41 | 4.59 | 3.99 |
| EV / EBITDA | 13.17 | 12.54 | 20.63 | 20.86 | 16.27 | 21.44 | 24.85 | 31.00 | 22.16 | 40.78 | 21.06 |
| EV / EBIT | 42.29 | — | 66.51 | 37.03 | 22.23 | 28.35 | 45.10 | 55.23 | 40.08 | 117.70 | 34.08 |
| EV / FCF | — | — | 139.59 | 67.09 | 26.94 | 26.02 | 48.01 | 65.01 | 41.20 | 76.76 | 57.33 |
IART Profitability
Margins and return-on-capital ratios measuring operating efficiency
Integra LifeSciences Holdings Corporation earns an operating margin of 4.2%. Operating margins have compressed from 7.2% to 4.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -39.9% indicates the company is currently destroying shareholder equity. ROIC of 1.7% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.7% | 51.7% | 54.8% | 57.4% | 62.3% | 61.2% | 62.0% | 62.8% | 61.2% | 63.3% | 64.8% |
| Operating Margin | 4.2% | 4.2% | 1.8% | 7.2% | 15.3% | 12.8% | 11.0% | 6.2% | 7.5% | 3.8% | 11.6% |
| Net Profit Margin | -31.6% | -31.6% | -0.4% | 4.4% | 11.6% | 11.0% | 9.8% | 3.3% | 4.1% | 5.4% | 7.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.9% | -39.9% | -0.4% | 4.0% | 10.3% | 10.6% | 9.1% | 3.6% | 5.2% | 7.2% | 9.4% |
| ROA | -13.5% | -13.5% | -0.2% | 1.8% | 4.7% | 4.6% | 3.9% | 1.6% | 1.9% | 2.6% | 4.2% |
| ROIC | 1.7% | 1.7% | 0.7% | 2.8% | 6.2% | 5.3% | 4.2% | 2.7% | 3.2% | 1.7% | 6.1% |
| ROCE | 2.2% | 2.2% | 0.9% | 3.2% | 6.8% | 5.9% | 4.9% | 3.2% | 3.9% | 2.0% | 6.9% |
IART Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Integra LifeSciences Holdings Corporation carries a Debt/EBITDA ratio of 9.3x, which is highly leveraged (185% above the sector average of 3.3x). Net debt stands at $1.8B ($2.0B total debt minus $235M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.95 | 1.95 | 1.28 | 1.06 | 0.90 | 0.99 | 1.09 | 1.03 | 0.98 | 1.91 | 0.79 |
| Debt / EBITDA | 9.27 | 9.27 | 11.75 | 7.15 | 4.53 | 5.19 | 6.12 | 7.17 | 5.97 | 13.77 | 3.54 |
| Net Debt / Equity | — | 1.72 | 1.12 | 0.89 | 0.65 | 0.68 | 0.78 | 0.89 | 0.88 | 1.73 | 0.67 |
| Net Debt / EBITDA | 8.20 | 8.20 | 10.29 | 5.98 | 3.26 | 3.59 | 4.38 | 6.19 | 5.36 | 12.46 | 2.99 |
| Debt / FCF | — | — | 69.63 | 19.23 | 5.40 | 4.36 | 8.47 | 12.99 | 9.97 | 23.45 | 8.15 |
| Interest Coverage | -5.53 | -5.53 | 0.74 | 2.58 | 5.31 | 4.82 | 2.08 | 2.11 | 1.94 | 1.32 | 4.50 |
IART Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Integra LifeSciences Holdings Corporation's current ratio of 2.54x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.46x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.45x to 2.54x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.54 | 2.54 | 1.17 | 3.45 | 3.62 | 3.39 | 3.09 | 2.59 | 2.95 | 2.36 | 4.01 |
| Quick Ratio | 1.46 | 1.46 | 0.71 | 2.18 | 2.61 | 2.46 | 2.31 | 1.64 | 1.88 | 1.51 | 2.25 |
| Cash Ratio | 0.58 | 0.58 | 0.30 | 1.01 | 1.42 | 1.51 | 1.17 | 0.60 | 0.53 | 0.50 | 0.83 |
| Asset Turnover | — | 0.45 | 0.40 | 0.41 | 0.40 | 0.41 | 0.38 | 0.46 | 0.47 | 0.37 | 0.55 |
| Inventory Turnover | 1.60 | 1.60 | 1.70 | 1.69 | 1.81 | 1.88 | 1.68 | 1.79 | 2.04 | 1.47 | 1.61 |
| Days Sales Outstanding | — | 62.24 | 61.73 | 61.40 | 61.74 | 54.86 | 60.01 | 66.21 | 65.87 | 77.35 | 54.52 |
IART Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Integra LifeSciences Holdings Corporation returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 1.9% | 3.9% | 3.0% | 2.4% | 1.0% | 1.6% | 1.7% | 2.2% |
| FCF Yield | — | — | 1.4% | 2.1% | 4.6% | 4.6% | 2.5% | 1.9% | 3.2% | 1.9% | 2.0% |
| Buyback Yield | 0.0% | 0.0% | 3.0% | 7.9% | 2.7% | 0.0% | 1.8% | 0.0% | 0.0% | 0.2% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 3.0% | 7.9% | 2.7% | 0.0% | 1.8% | 0.0% | 0.0% | 0.2% | 0.1% |
| Shares Outstanding | — | $77M | $77M | $80M | $84M | $85M | $85M | $86M | $84M | $79M | $79M |
Peer Comparison
Compare IART with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IARTYou | $1B | -2.1 | 13.2 | — | 51.7% | 4.2% | -39.9% | 1.7% | 9.3 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ATRC | $1B | -116.7 | 78.4 | 29.4 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 NTRA | $30B | -140.6 | — | 427.2 | 60.3% | -13.1% | -19.4% | -33.3% | — |
 MMSI | $4B | 28.9 | 12.9 | 17.0 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 LMAT | $3B | 43.7 | 34.1 | 33.7 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 GMED | $12B | 22.8 | 19.4 | 20.5 | 67.4% | 16.3% | 12.3% | 8.9% | 0.2 |
 AORT | $2B | 165.2 | 38.8 | — | 61.3% | 6.1% | 2.7% | 3.2% | 5.9 |
 TMDX | $3B | 15.0 | 18.4 | 18.9 | 59.9% | 17.9% | 54.2% | 18.8% | 3.5 |
 ANGO | $459M | -13.3 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See IART's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IART Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IART vs HOLX
Side-by-side business, growth, and profitability comparison vs Hologic, Inc..
Start ComparisonIART — Frequently Asked Questions
Quick answers to the most common questions about buying IART stock.
What is Integra LifeSciences Holdings Corporation's P/E ratio?
Integra LifeSciences Holdings Corporation's current P/E ratio is -2.1x. The historical average is 41.2x.
What is Integra LifeSciences Holdings Corporation's EV/EBITDA?
Integra LifeSciences Holdings Corporation's current EV/EBITDA is 13.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 22.9x.
What is Integra LifeSciences Holdings Corporation's ROE?
Integra LifeSciences Holdings Corporation's return on equity (ROE) is -39.9%. The historical average is 0.5%.
Is IART stock overvalued?
Based on historical data, Integra LifeSciences Holdings Corporation is trading at a P/E of -2.1x. Compare with industry peers and growth rates for a complete picture.
What are Integra LifeSciences Holdings Corporation's profit margins?
Integra LifeSciences Holdings Corporation has 51.7% gross margin and 4.2% operating margin.
How much debt does Integra LifeSciences Holdings Corporation have?
Integra LifeSciences Holdings Corporation's Debt/EBITDA ratio is 9.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.